July 2008 Volume 26 Number 7, pp 715 - 836
Visit Nature Biotechnology online to browse the journal.
Now available at http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0dXt0EW
Please note that you need to be a subscriber to enjoy full text access to Nature Biotechnology online. To purchase a subscription, please visit:
http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0aAP0EU
Alternatively, to recommend a subscription to your library, please visit
http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BRQi0E1
Bioentrepreneur: an online resource for budding business in the life sciences.
http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BkE0EU
=====================================================================
=====================================================================
THE SOURCE EVENT - London, 26/09/2008
The Source Event is a dedicated science career fair from Naturejobs. Meet 1-1 with employers from across Europe looking to fill hundreds of vacancies. REGISTER NOW for the conference and workshop sessions: http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BwBw0Ec
Post your career questions for The Source Event speakers before the event in the online discussion forum: http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BYIT0Ee
=====================================================================
=====================================================================
BIOPARTNERING
Visit our Biopartnering site to view Company Profiles and Partnership Opportunities:
http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BpT40Eg
=====================================================================
=====================================================================
SciBX: Science-Business eXchange:
Saves you time and resources by identifying and describing key translational research.
Provides scientific and commercial perspectives on the key papers.
Identifies novel competition.
Facilitates early opportunities for investment, alliances and partnerships.
Subscribe today at http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BktW0Ei
=====================================================================
=====================================================================
----------------------
EDITORIALS
----------------------
The other path for follow-ons p715
With follow-on biologics essentially dead in the water in the US, the decision of the world's largest generics manufacturer to invest in a platform for enhancing protein pharmacokinetics could pay dividends.
doi:10.1038/nbt0708-715
http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzOu0Eq
In need of counseling? p716
Moves to clamp down on companies offering direct-to-consumer genetic tests are out of step with personal genomics and its potential to empower individuals' role in their own healthcare.
doi:10.1038/nbt0708-716
http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzOv0Er
----------------------
NEWS
----------------------
[euro]2 billion IMI launched with European pharma pp717 - 718
John Hodgson
doi:10.1038/nbt0708-717
http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzOw0Es
Dyax backs albumin p718
Mark Ratner
doi:10.1038/nbt0708-718
http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzOx0Et
Commercial interest waxes for IGF-1 blockers pp719 - 720
Randy Osborne
doi:10.1038/nbt0708-719
http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzOy0Eu
Meta-analysis torpedoes blood substitutes pp721 - 723
Charlie Schmidt
doi:10.1038/nbt0708-721a
http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzOz0Ev
UK passes hybrids p721
Nuala Moran
doi:10.1038/nbt0708-721b
http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzO10Ei
Tighter gene tests p721
Jeff Fox
doi:10.1038/nbt0708-721c
http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzO20Ej
Biofuels, take two p722
Emily Waltz
doi:10.1038/nbt0708-722a
http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzO30Ek
50 cancers to be sequenced p722
Henry Nicholls
doi:10.1038/nbt0708-722b
http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzO40El
Pfizer jettisons Esperion pp724 - 725
Catherine Shaffer
doi:10.1038/nbt0708-724
http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzO50Em
Genetically modified mosquitoes p725
Susan Aldridge
doi:10.1038/nbt0708-725a
http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzO60En
Pan-EU Biobanks p725
Barbara Nasto
doi:10.1038/nbt0708-725b
http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzO70Eo
Profile: Julian Davies p727
An icon of the European biotech industry and a pioneer of metagenomics, Julian Davies continues to pursue his lifelong love affair with microbiology.
George S. Mack
doi:10.1038/nbt0708-727
http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzO80Ep
DATA PAGE
State of the biotech sector[mdash]2007 p728
Stacy Lawrence
doi:10.1038/nbt0708-728
http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzPA0Ez
NEWS FEATURE
Poised to branch out pp729 - 732
Although dendrimers have not yet taken the drug industry by storm, biomedical research and industrial applications of these tiny, highly branched molecules continue to grow. Vivien Marx reports.
Vivien Marx
doi:10.1038/nbt0708-729
http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzPB0E1
----------------------
BIOENTREPRENEUR
----------------------
BUILDING A BUSINESS
Preparing for (and avoiding) the courtroom pp733 - 735
Intellectual property (IP) is often the most valued asset of biotech firms, especially startups. Two IP lawyers offer guidance on avoiding suits altogether, when to settle them and when to fight.
Jeff Wolfson and Russ Emerson
doi:10.1038/bioe.2008.6
http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzPC0E2
----------------------
OPINION AND COMMENT
----------------------
CORRESPONDENCE
Europe to ban direct-to-consumer genetic tests? pp736 - 737
Pascal Borry
doi:10.1038/nbt0708-736
http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzPD0E3
Dichotomies between computational and mathematical models pp737 - 738
C Anthony Hunt, Glen E P Ropella, Sunwoo Park and Jesse Engelberg
doi:10.1038/nbt0708-737
http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzPE0E4
Reply to Dichotomies between computational and mathematical models pp738 - 739
doi:10.1038/nbt0708-738
http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzPF0E5
HLA-haplotype banking and iPS cells pp739 - 740
Norio Nakatsuji, Fumiaki Nakajima and Katsushi Tokunaga
doi:10.1038/nbt0708-739
http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzPG0E6
Global mRNA changes in microarray experiments pp741 - 742
Matthew A Hannah, Henning Redestig, Andrea Leisse and Lothar Willmitzer
doi:10.1038/nbt0708-741
http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzPH0E7
COMMENTARY
(Re)defining biopharmaceutical pp743 - 751
Vested interests are redefining, rebranding and co-opting what is 'biopharmaceutical'. This is not just a matter of semantics[mdash]the core identity of the biotech industry and its products is at stake.
Ronald A Rader
doi:10.1038/nbt0708-743
http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzPI0E8
----------------------
FEATURES
----------------------
Public biotech 2007 - the numbers pp753 - 762
Record profits and financing in the public biotech sector may be unsustainable in the coming years as economies falter.
Stacy Lawrence and Riku Lahteenmaki
doi:10.1038/nbt0708-753
http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzPJ0EA
PATENTS
How many patents does a biopharmaceutical company need? pp763 - 766
Young biotech companies may not need extensive patent portfolios to survive or grow.
Deepak Kumar Parida, Ritu Mehdiratta and Gayatri Saberwal
doi:10.1038/nbt0708-763
http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzPK0EB
Recent patent applications in mass spectrometry p767
doi:10.1038/nbt0708-767
http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzPL0EC
----------------------
NEWS AND VIEWS
----------------------
Hitting the mother lode of tumor angiogenesis pp769 - 770
An oral formulation of an antiangiogenic drug may allow long-term anti-cancer therapy.
Daylon James, Sina Rabbany and Shahin Rafii
doi:10.1038/nbt0708-769
http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzPM0ED
Setting the standard in synthetic biology pp771 - 774
Standards for characterization, manufacture and sharing of information about modular biological devices may lead to a more efficient, predictable and design-driven genetic engineering science.
Adam Arkin
doi:10.1038/nbt0708-771
http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzPN0EE
The long and short of carbon nanotube toxicity pp774 - 776
Toxicological and pharmacological studies suggest guidelines for the safe use of carbon nanotubes in medicine.
Kostas Kostarelos
doi:10.1038/nbt0708-774
http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzPO0EF
Research Highlights p777
doi:10.1038/nbt0708-777
http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzPP0EG
----------------------
RESEARCH
----------------------
ANALYSIS
A Bayesian deconvolution strategy for immunoprecipitation-based DNA methylome analysis pp779 - 785
Thomas A Down et al.
doi:10.1038/nbt1414
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzPQ0EH
Article: http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzPR0EI
PERSPECTIVE
Refinement and standardization of synthetic biological parts and devices pp787 - 793
Barry Canton, Anna Labno and Drew Endy
doi:10.1038/nbt1413
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzPS0EJ
Article: http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzPT0EK
BRIEF COMMUNICATIONS
Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds pp795 - 797
Danwei Huangfu et al.
doi:10.1038/nbt1418
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzPU0EL
Article: http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzPV0EM
ARTICLES
An orally delivered small-molecule formulation with antiangiogenic and anticancer activity pp799 - 807
Widespread use of antiangiogenic drugs for cancer therapy is limited in part by the requirement for intravenous injection. Benny et al. describe an oral formulation of an antiangiogenic small molecule that inhibits tumor growth and prevents liver metastases in mice.
Ofra Benny et al.
doi:10.1038/nbt1415
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzPW0EN
Article: http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzPX0EO
Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases pp808 - 816
Elena E Perez et al.
doi:10.1038/nbt1410
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzPY0EP
Article: http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzPZ0EQ
Treatment of arthritis with a selective inhibitor of c-Fos/activator protein-1 pp817 - 823
Therapies that target only one inflammatory cytokine such as tumor necrosis factor [alpha] are often insufficient to treat rheumatoid arthritis. Aikawa et al. show that a small molecule targeting c-Fos/AP-1, a transcription factor that regulates both inflammatory cytokines and matrix metalloproteinases, inhibits type II collagen-induced arthritis in mice.
Yukihiko Aikawa et al.
doi:10.1038/nbt1412
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzPa0EX
Article: http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzPb0EY
LETTER
Electrostatic readout of DNA microarrays with charged microspheres pp825 - 830
Microarray readout by electrostaticsMicroarray platforms usually rely on fluorescence detection. Clack et al. present an equally sensitive, label-free technique that electrostatically detects DNA or RNA hybridization after randomly dispersing charged microspheres onto the microarray surface.
Nathan G Clack, Khalid Salaita and Jay T Groves
doi:10.1038/nbt1416
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzPc0EZ
Article: http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzPd0Ea
----------------------
CORRIGENDA
----------------------
Corrigendum: Large-scale chemical dissection of mitochondrial function p831
Bridget K Wagner et al.
doi:10.1038/nbt0708-831a
http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzPe0Eb
Corrigendum: Isolation and directed differentiation of neural crest stem cells derived from human embryonic stem cells p831
Gabsang Lee et al.
doi:10.1038/nbt0708-831b
http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzPf0Ec
----------------------
ERRATA
----------------------
Erratum: Looking forward, looking back p831
doi:10.1038/nbt0708-831c
http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzPg0Ed
Erratum: Is personalized medicine finally arriving? p831
Malorye Allison
doi:10.1038/nbt0708-831d
http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzPh0Ee
----------------------
NATUREJOBS
----------------------
CAREERS AND RECRUITMENT
A walk through the Valley of Death pp833 - 834
Expert tips for acquirers and acquirees to get through a difficult post-merger integration.
Mari Paul
doi:10.1038/nbt0708-833
http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzPi0Ef
PEOPLE
People p836
doi:10.1038/nbt0708-836
http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BzPj0Eg
=====================================================================
Journal of Medical Marketing - recommend to your librarian!
http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BCof0EE
Why wait? Get unlimited desktop access to Journal of Medical Marketing. The Journal provides executives performing a marketing or commercial role at companies producing pharmaceuticals, medical devices or diagnostic equipment for the medical industry with new ideas, the latest intelligence and best practice, making it an indispensable resource.
To recommend the Journal to your librarian click here
http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0BrnD0EQ
=====================================================================
You have been sent this Table of Contents Alert because you have opted in to
receive it. You can change or discontinue your e-mail alerts at any time,
by modifying your preferences on your nature.com account at:
http://ealerts.nature.com/cgi-bin24/DM/y/emCl0Xztnp0HjC0Zzu0Ev
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2008 Nature Publishing Group
=====================================================================
